SEC Tracker
Get the app

NextCure NXTC

NextCure fires CMO ahead of merger

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Dr. Udayan Guha's employment terminated Oct 31, 2026
  2. Severance agreement includes benefits for termination without cause
  3. Additional severance depends on merger closing
  4. Dr. Guha's departure follows pending merger with Avere Therapeutics

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when NextCure files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing cites the company's decision to terminate Dr. Guha's employment in contemplation of a pending merger with Avere Therapeutics, Inc. The filing also mentions a severance agreement and release between Dr. Guha and the company.
  2. It also notes that the severance agreement includes additional benefits if the merger closes, based on a change in control provision in his employment agreement.
  3. The company expressed gratitude for Dr. Guha's contributions and leadership during his tenure.
  4. The Form 8-K was signed by Steven P.

4 of 4 claims matched the filing text.

From the filing

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 26, 2026 NextCure, Inc. (the Company ) determined that the employment of Dr. Udayan Guha, M.D., Ph.D., Chief Medical Officer and a named executive officer of the Company, will be terminated effective October 31, 2026, in contemplation of the pending merger of the Company and Avere Therapeutics, Inc1 (the Merger ).

In connection with his departure, Dr. Guha entered into a severance agreement and release with the Company (the Severance Agreement ). In exchange for a release of claims in favor of the Company, the Severance Agreement provides for severance benefits consistent with those provided for a termination without cause under Dr. Guha s existing employment agreement, as described in the Company s Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 24, 2026 (the Employment Agreement ). Subject to and conditioned upon the occurrence of the closing of the Merger, the Severance Agreement provides for additional severance equal to the enhanced severance benefits for a termination without cause in relation to a change in control, as set forth in Dr. Guha s Employment Agreement2.

The Company and its Board of Directors thank Dr. Guha for his leadership at the Company and are grateful for his many valuable contributions during his tenure3.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November

Dated: October 30, 2026

NEXTCURE, INC.

By:4

/s/ Steven P. Cobourn4

Name:

Steven P. Cobourn

Title:

Chief Financial Officer

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Cellectar Biosciences CLRB public float $13M, Jun 30, 2025
  2. Synergy CHC SNYR public float $13M, Jun 30, 2025
  3. Cypherpunk Technologies CYPH public float $12M, Jun 30, 2025
  4. Earth Science Tech ETST public float $14M, Mar 31, 2026
  5. Cocrystal Pharma COCP public float $12M, Jun 30, 2025